APA (7th ed.) Citation

Wang, L., Chen, X., Zhao, J., Tang, J., Tang, W., Liao, B., & Nian, W. Therapy of genomic unstable solid tumours (WHO grade 3/4）in clinical stage III/IV using individualised neoantigen tumour peptides-INP trial (individualised neoantigen tumour peptides immunotherapy): Study protocol for an open-label, non-randomised, prospective, single-arm trial. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Wang, Ling, Xia Chen, Juan Zhao, Jiaxi Tang, Wanyan Tang, Bin Liao, and Weiqi Nian. Therapy of Genomic Unstable Solid Tumours (WHO Grade 3/4）in Clinical Stage III/IV Using Individualised Neoantigen Tumour Peptides-INP Trial (individualised Neoantigen Tumour Peptides Immunotherapy): Study Protocol for an Open-label, Non-randomised, Prospective, Single-arm Trial. BMJ Publishing Group.

MLA (9th ed.) Citation

Wang, Ling, et al. Therapy of Genomic Unstable Solid Tumours (WHO Grade 3/4）in Clinical Stage III/IV Using Individualised Neoantigen Tumour Peptides-INP Trial (individualised Neoantigen Tumour Peptides Immunotherapy): Study Protocol for an Open-label, Non-randomised, Prospective, Single-arm Trial. BMJ Publishing Group.